LL-37 vs Thymosin Alpha-1 — Peptide Comparison

LL-37 vs Thymosin Alpha-1 — Peptide Comparison LL-37 vs Thymosin Alpha-1 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range LL-37 0.5–1.6 mg/mL (topical) Thymosin Alpha-1 1.6–3.2 mg Frequency Once daily Twice weekly Administration Topical application (wound healing) Subcutaneous injection Cycle Length 12+ weeks 8-12 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Moderate human trials (Phase 1-2) Efficacy Wound Healing Fighting Infections Immune Boost Immune Activation Infection Fighting Immune Balance Technical Data Molecular Formula C205H340N60O53 Molecular Weight 4,493.26 Da Half-Life Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes Bioavailability Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery CAS Number 154947-66-7 C129H215N33O55 3108.32 g/mol Approximately 2 hours High when injected subcutaneously (rapid absorption, peak at ~2 hours) 62304-98-7 Protocols starting 0.5 mg/mL gel 4 weeks Lowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4]. standard 1.6 mg/mL gel Mid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4]. 1.6 mg Twice weekly (3-4 days apart) 6-12 months Established clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4]. advanced 1.6 mg daily, then 1.6 mg twice weekly Daily for an initial loading period, then twice weekly Some immune-adjuvant and acute protocols front-load with daily dosing before settling to the standard twice-weekly schedule [4][6]. Applications Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Anti-biofilm strategies for chronic wound infections and medical device-associated infections LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Boosting innate immune defense in immunocompromised or aging individuals LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Chronic Hepatitis B or C Support Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment. Cancer Treatment Support When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments. Age-Related Immune Decline As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time. Severe Infection Recovery In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability. Safety Profile Common Local site irritation Transient stinging or burning Mild perilesional erythema Increased wound exudate Uncommon Allergic contact reaction Serious Hemolytic activity at systemic concentrations Injection site reactions Mild fatigue Flu-like symptoms Mild fever Lymph node awareness Allergic reaction Research Status FDA Status Research compound Safety Overview LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications. Contraindications xKnown hypersensitivity to cathelicidin peptides or formulation components xActive hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity xPregnancy and breastfeeding — insufficient reproductive safety data from clinical trials xSevere renal impairment — peptide clearance may be altered FDA approved for other use Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions. xOrgan transplant recipients on immunosuppressants xActive autoimmune disease flares xKnown allergy to thymosin peptides xPregnancy or breastfeeding xChildren under 18 without medical supervision Decision Guide Choose LL-37 if... Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) Anti-biofilm strategies for chronic wound infections and medical device-associated infections Boosting innate immune defense in immunocompromised or aging individuals Choose Thymosin Alpha-1 if... Immune system strengthening Chronic infection support Cancer adjunct therapy Healthy aging immune support